Search

8 Dec 2007: DOI: 10.1126/science.1135394 , 239 (2007); 317Science. et al.Nabil Miled,the Phosphoinositide 3-Kinase Catalytic SubunitMechanism of Two Classes of Cancer Mutations in. www.sciencemag.org (this information is current as of December 8, 2007 ):The

20 Apr 2002: Proc. Natl. Acad. Sci. USAVol. 94, pp. 9637–9642, September 1997Biophysics. The 2.0-Å resolution crystal structure of a trimeric antibodyfragment with noncognate VH–VL domain pairs shows arearrangement of VH CDR3XUE Y. PEI, PHILIPP HOLLIGER,

2 Aug 2010: DOI: 10.1126/science.1184429 , 1638 (2010); 327Science. et al.Simon Miller,the Structure of the Lipid Kinase Vps34Shaping Development of Autophagy Inhibitors with. This copy is for your personal, non-commercial use only. clicking herecolleagues,

5 Dec 2012: 253), ra89. [DOI: 10.1126/scisignal.2003264] 5Science SignalingRoger L. Williams and Jonathan M. Backer (4 December 2012) Harden, Alan V. Smrcka, Ronald Taussig, Anne R. Bresnick, Bernd Nürnberg, Christine Hsueh, Olga Perisic, Christian Harteneck,

11 Jun 1997: Phosphoinositide-specific phospholipase C: structural basisfor catalysis and regulatory interactionsMatilda Katan and Roger L. Williams. Phosphoinositide-specific phospholipase C (PI-PLC) isozymeshave an important role in cellular responses to a

8 Dec 2007: LETTERS. Structural basis for selective recognition of ESCRT-IIIby the AAA ATPase Vps4Takayuki Obita1, Suraj Saksena2, Sara Ghazi-Tabatabai1, David J. Gill1, Olga Perisic1, Scott D. Emr2. & Roger L. Williams1. The AAA1 ATPases are essential for

6 May 1999: Article No. jmbi.1999.2720 available online at http://www.idealibrary.com on J. Mol. Biol. (1999) 288, 649657. Crystal Structure of the Two N-terminal Domains ofg3p from Filamentous Phage fd at 1.9 AÊ : Evidence forConformational Lability. Philipp

20 Apr 2002: Crystal Structure of a Calcium-Phospholipid Binding Domainfrom Cytosolic Phospholipase A2. (Received for publication, September 24, 1997). Olga Perisic‡, Sun Fong, Denise E. Lynch‡, Mark Bycroft, and Roger L. Williams‡. From the ‡Medical

25 Nov 2012: Oncogenic mutations mimic and enhance dynamicevents in the natural activation of phosphoinositide3-kinase p110α (PIK3CA)John E. Burke, Olga Perisic, Glenn R. Masson, Oscar Vadas, and Roger L. Williams1. Laboratory of Molecular Biology, Medical

12 Nov 2006: Phosphoinositide 3-kinases as drug targets in cancerLen Stephens1, Roger Williams2 and Phillip Hawkins1. The past two years have seen phosphoinositide 3-kinases. (PI3Ks) move from being seen as potential targets for. chemotherapeutics, to one of